On Dec. 12, the Cambridge, Mass.-based company said several leaders, including Chief Medical Officer Baisong Mei, MD, PhD, will depart during this transition.
Editas said the restructuring will “extend its cash runway” into the second quarter of 2027 and “accelerate its intent to achieve in vivo human proof of concept in approximately two years.”
The company also reported preclinical achievements in liver and blood stem cell research.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.